{"id":"W2602281547","doi":"10.1200/jco.2017.35.4_suppl.660","title":"Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Irinotecan; Gastroenterology; Colorectal cancer; Clinical endpoint; Regorafenib; Refractory (planetary science); Oxaliplatin; Progression-free survival; Placebo; Clinical trial; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001711425,0.001039311,0.001952152,0.0004605424,0.0002113827,0.0007329311,0.000547238,0.0008469025,0.003792925],"category_scores_gemma":[0.0013272,0.000432886,0.002152227,0.0004013708,0.0006586704,0.0006030225,0.0004289829,0.001656743,0.0005455909],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007726288,"about_ca_system_score_gemma":0.0008728065,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009242421,"about_ca_topic_score_gemma":0.003231286,"domain_scores_codex":[0.9994407,0.0003489934,0.00004271805,0.00007179681,0.0000308013,0.00006487205],"domain_scores_gemma":[0.9993652,0.0001819161,0.000182311,0.00004023231,0.00003577561,0.0001947198],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9745405,0.003750281,0.001135817,0.0006860087,0.001797386,0.00003399143,0.00004746673,0.0004435949,0.003127215,0.00004803702,0.0004031799,0.01398663],"study_design_scores_gemma":[0.74146,0.2422862,0.009096056,0.00008147927,0.003307291,0.0000897853,0.00005260827,0.0007438275,0.001248576,0.0001833632,0.001428352,0.00002243329],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891139,0.004556668,0.0004782325,0.0003288231,0.00021652,0.002782146,0.001010421,0.00005219256,0.001461135],"genre_scores_gemma":[0.9924689,0.002143228,0.0006530739,0.0003314485,0.0001555791,0.001647599,0.0006551334,0.00000946218,0.001935591],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003792925,"threshold_uncertainty_score":0.01268858,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09893982140482208,"score_gpt":0.4757736319774503,"score_spread":0.3768338105726282,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}